Serina Therapeutics, Inc. · AMEX:SER
Serina Therapeutics — AgeX Therapeutics — Rodman & Renshaw Global Investment Conference 2019
33 slides from Serina Therapeutics's conference presentation, Sep 9, 2019
Slide 1: Rodman & Renshaw Global Investment Conference
NYSE American: AGE Rodman & Renshaw Global Investment Conference September 9, 2019
Slide 2: Forward Looking Statements
Forward Looking Statements The matters discussed in this presentation include forward looking statements which are subject to various risks, uncertainties, and other factors that could cause actual results to differ materially from the results anticipated. Such risks and uncertainties include but ar
Slide 3: Mission
Mission To target the largest and most rapidly-growing markets in medicine: Age-Related Degenerative Disease An advanced technology that reverses aging and induces regeneration in human cells and tissues AGEX THERAPEUTICS
Slide 4: Significant Biotechnology Revolutions
Significant Biotechnology Revolutions Recombinant DNA Technology Monoclonal Antibodies Regenerative Medicine AGEX. P THERAPEUTICS
Slide 5: The Power of Pluripotency
The Power of Pluripotency Key applications in age-related degenerative disease Uniform and infinitely-scalable product Enables precise genetic modification Off-the-shelf products 9 = Te ee rm ae | Mesoderm — AGEX. Pluripotent Stem Cells THERAPEUTICS .* Endoderm
Slide 6: Pluripotency — The Competitive Edge
Pluripotency — The Competitive Edge The >1000-fold complexity of cell types derived from hPS cells leads to unique challenges: Pluripotent Cells Activin A FGF2 TGFp3 * How manufacture with cGMP? * How produce allogeneic product? ¢ Identity - Lot-to-lot variability in composition * Purity — Contamina
Slide 7: Proprietary Technologies
Proprietary Technologies >400 patents & patent apps worldwide in pluripotency- based therapeutics: > PureStem® manufacturing technology AGEX THERAPEUTICS
Slide 8: Universal PureStem™ Technology
Universal PureStem™ Technology “od ” - _ < = = 2 Za a f sa Ss sas S 2 = SS cs zg ° — _ D> ~ i _ § Ja e — ~ =e © > =e = > < < <a => é = = =a Ss pesos 2 vi Get => T= < — 3 bs 2 tl — g ~ — > o> > => eas Z fi f zs & Purification o} ES Cells Differentiation desired cell type Problem of impurities ¥ Fy .
Slide 9: Proprietary Technologies
Proprietary Technologies > UniverCyte™ (HLA-C G fo mask rejection) technology of choice for cell-based therapies AGEX THERAPEUTICS
Slide 10: UniverCyte™: HLA-G for Allogeneic Immunotolerance
UniverCyte™: HLA-G for Allogeneic Immunotolerance * Inhibition of cytotoxicity * Inhibition of IFN-ysecretion Be * Inhibition of MICA/NKG2D activation # The primary role of HLA- NK cells * Inhibition of chemotaxis Gis to suppress maternal Hes, e7 : iii of anc eae space production Neutrophils Immune
Slide 11: Value of the UniverCyte Allogeneic Products
Value of the UniverCyte Allogeneic Products Classical biologics off-the-shelf business model Traditional Biologicals Nini Centralized Distributed Production =) Frozen => Point Of Care Facility Inventory -- = UniverCyte- Derived Cell Therapy Products AGEX, THERAPEUTICS a
Slide 12: Proprietary Technologies
Proprietary Technologies > HyStem matrix for stable engraftment AGEX THERAPEUTICS
Slide 13: The Ideal Regenerative Platform
The Ideal Regenerative Platform Twin Technologies: Cells & Matrix Pluripotent Cell- Based Therapeutics pat cf Et a i Pluripotent Stem Cells (PSCs) allow the manufacture of all young human cell types on an industrial scale PureStem-based purity AGEX THERAPEUTICS HyStem® Matrix Delivery 10° 10° 107 10
Slide 14: Induced Tissue Regeneration (iTR™)
Proprietary Technologies >» HyStem® matrix for stable engraft Induced Tissue Regeneration (iTR™) AGEX THERAPEUTICS
Slide 15: iTR or “Partial Reprogramming”
iTR or “Partial Reprogramming” TransTech Alert Transformational Technology EGS svgust 08, 2019 The Race for Age Reversal Heats Up Reversal of ageing- and injury-induced vision loss by Tet-dependent In Vivo Amelioration of Age-Associated Hallmarks by epigenetic reprogramming Partial Reprogramming Gra
Slide 16: Reversing the Aging of Human Cells
Reversing the Aging of Human Cells OK; ¢ ‘ Re & Reprogramming L’L? SY 2 oe SSS TRE (kb) Methylation Age A Data 77 p = 1e-14 —21.2 18 16 . . 7 Somatic Primary Tissue 14 2 - 74 E 40 = 61 A | ips - 5.0 - 42 e | ES - 3.6 ownononsd =~ -— NN m.age Regen Med 2010 May:5(3):345-63 AGEX THERAPEUTICS Genome Bi
Slide 17: iTR Strategy
iTR Strategy Twin Strategies in Development Load with Small Molecule Telomerase mRNA Cocktail (TR 1547) ReCyte1 EC Cell Line Exosomes In Vivo Applications vA AGEX. 3 THERAPEUTICS
Slide 18: Drug-Based iTR
Drug-Based iTR COX7A1 Pluripotent (off) alli Wi i AGEX-iTR1547 ae : Embryonic/ 1500 j Fetal Levels > | | | | | 500 = ij duit Hl AGEX a . THERAPEUTICS RFUs
Slide 19: Maximizing Commercialization of the Platform
Maximizing Commercialization of the Platform é . ® ' ~ Pluripotent : ae 4 = Stem Cells ; ] s | i . & [ se 0) = * |; * Ectopic Organoid-Based Therapeutics Drug Discovery Biomaterials 19
Slide 20: Business Strategy
Business Strategy Bailment of Master Cell Banks (MCBs) AGEX THERAPEUTICS
Slide 21: Bailment of Master Cell Banks
Bailment of Master Cell Banks Master Cell Banks AgeX retains ownership of MCB ae? = - Licensee owns derivative products fe gg ESS in defined fields of use @ - Royalty is not patent-based and gp” therefore runs into indefinite future Cellular Therapeutics - Results in potentially high NPV AGEX THERAP
Slide 22: Business Strategy: Partnerships for non-core applications
Business Strategy Partnerships for non-core applications >» Therapeutic use of ectopic organoids > Diverse biomaterials including exosomes >» Cytiva Il - Adult cardiac cells for drug testing AGEX THERAPEUTICS
Slide 23: Business Strategy: Internal development
Business Strategy a IVa Ii dult cardiac cells f rug tes Internal development of AGEX-BAT1, AGEX-VASC17, and Renelon AGEX THERAPEUTICS
Slide 24: Brown Adipose Cells Regulate Metabolism
Brown Adipose Cells Regulate Metabolism Maintenance S Weight Gain Weight Loss T2 Diabetes AGEX THERAPEUTICS
Slide 25: Brown Adipose Cells Regulate Metabolism
Brown Adipose Cells Regulate Metabolism a 70-5 d 405 ia 35 ie 80-4483) = P< 0.01 i & 504 ZF 94 b e xt S 257 3 404 5 ro} fo} 204 °° 8 304 5 5 S154 5 20-4 8 £ ma 1075 104 we 0-7 07 20s 30s 40s 50s 60- 20s 30s 40s 50s 60- Age Age Obesity (2011) 19, 1755-1760. doi:10.1038/oby.2011.125 AGEX a THERAPEUTIC
Slide 26: AgeX-BAT1 Properties
AgexX-BAT1 Properties Stained for Brown Adipocyte Marker Stem Cell Research & Therapy (2019) 10:7 Tissue-Sourced Brown Adipocytes PureStem Brown Adipocytes AGEX 26 THERAPEUTICS
Slide 27: Obesity/T2D Market/Competition
Obesity/T2D Market/Competition * 30MAmericans have diabetes’ 1:3 Americans will have diabetes by 2050 ¢ The global market for diabetes mellitus and obesity is set to rise from $70.8 billion in 2015 to $163.2 billion by 2022, at a strong compound annual growth rate of 12.7%, according to business int
Slide 28: AgeX-VASC7 Purity
AgeX-VASC7 Purity Monoclonal Endothelium CD31/VECAD/GFP-MV2-6 ~100% Purity < Jy) & Y, 2 ie a 2 “ : eo a GFP Endothelium (168 hrs) 5 8 4 Soy 107 10 10* 10° VECAD APC-A M@-CD3ttcells M-CD34tcells_m - TIEZ*cells ~~ 28 THERAPEUTICS
Slide 29: Cardiovascular Market
Cardiovascular Market > STrillion Market Worldwide American American Heart | Stroke Association | Association ‘$555 billion | $1.1 trillion The Cost Generators: Aging Baby Boomers AGEX i THERAPEUTICS
Slide 30: Business Strategy: iTR through Reverse Bioengineering
Business Strategy nd Renelor Induced Tissue Regeneration (iTR™) through the subsidiary Reverse Bioengineering, Inc. AGEX s THERAPEUTICS
Slide 31: Anticipated Six Month Milestones
Anticipated Six Month Milestones Partnerships: >» Therapeutic use of ectopic organoids > First commercial bailment of master cell bank > PureStem-derived biomaterials Finance Reverse Bioengineering, Inc. to advance iTR Complete development of Cytiva // Announce development plans for Renelon™, a rela
Slide 32: Company Quick Facts and Executive Management
Company | COMPANY QUICK FACTS Founded 2017 Contact Details: 965 Atlantic Avenue Alameda, CA 94501 Tel: +1 (510) 671-8370 Stock Listing NYSE American: AGE Market Cap (9/6/19) ~$100M EXECUTIVE MANAGEMENT Michael D. West, Ph.D. Chief Executive Officer Founder and first CEO Geron Corporation Gregory Bai
Slide 33: Targeting the largest unmet medical needs in the US
¢ Targeting the largest unmet medical needs in the US: chronic degenerative diseases of aging ¢ Partnering the non-core commercial applications of pluripotency ¢ Early/widespread commercialization through bailment of UniverCyte master cell banks ¢ Internal development of AGEX-BAT1, AGEX-VASC1, Renel
AgeX Therapeutics — Rodman & Renshaw Global Investment Conference 2019 on 6ix